Drugs Made In America Acquisition II (NASDAQ:DMII) Issues Quarterly Earnings Results

Drugs Made In America Acquisition II (NASDAQ:DMII) announced its earnings results on Friday. The company reported $0.07 earnings per share for the quarter, FiscalAI reports.

Drugs Made In America Acquisition II Stock Performance

DMII traded down $0.01 during trading on Friday, reaching $10.12. The stock had a trading volume of 5,125 shares, compared to its average volume of 114,100. The stock has a 50 day moving average of $10.10 and a two-hundred day moving average of $10.03. Drugs Made In America Acquisition II has a 1-year low of $9.86 and a 1-year high of $10.20.

Institutional Trading of Drugs Made In America Acquisition II

A number of hedge funds and other institutional investors have recently modified their holdings of DMII. Rivernorth Capital Management LLC bought a new position in Drugs Made In America Acquisition II during the first quarter valued at about $2,991,000. Sona Asset Management US LLC raised its position in Drugs Made In America Acquisition II by 66.7% in the first quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock worth $4,985,000 after acquiring an additional 200,000 shares in the last quarter. Kryger Capital LLC acquired a new stake in Drugs Made In America Acquisition II in the 1st quarter valued at about $3,088,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Drugs Made In America Acquisition II during the 1st quarter valued at about $19,960,000. Finally, Gabelli Funds LLC acquired a new position in shares of Drugs Made In America Acquisition II in the 1st quarter worth approximately $1,609,000.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.